661 related articles for article (PubMed ID: 22506276)
1. Cellular delivery of pyrenyl-arene ruthenium complexes by a water-soluble arene ruthenium metalla-cage.
Furrer MA; Schmitt F; Wiederkehr M; Juillerat-Jeanneret L; Therrien B
Dalton Trans; 2012 Jun; 41(24):7201-11. PubMed ID: 22506276
[TBL] [Abstract][Full Text] [Related]
2. Double targeting of tumours with pyrenyl-modified dendrimers encapsulated in an arene-ruthenium metallaprism.
Pitto-Barry A; Barry NP; Zava O; Deschenaux R; Dyson PJ; Therrien B
Chemistry; 2011 Feb; 17(6):1966-71. PubMed ID: 21274948
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of cytotoxicity by combining pyrenyl-dendrimers and arene ruthenium metallacages.
Pitto-Barry A; Zava O; Dyson PJ; Deschenaux R; Therrien B
Inorg Chem; 2012 Jul; 51(13):7119-24. PubMed ID: 22716166
[TBL] [Abstract][Full Text] [Related]
4. Delivery of floxuridine derivatives to cancer cells by water-soluble organometallic cages.
Yi JW; Barry NP; Furrer MA; Zava O; Dyson PJ; Therrien B; Kim BH
Bioconjug Chem; 2012 Mar; 23(3):461-71. PubMed ID: 22263930
[TBL] [Abstract][Full Text] [Related]
5. Drug delivery of lipophilic pyrenyl derivatives by encapsulation in a water soluble metalla-cage.
Mattsson J; Zava O; Renfrew AK; Sei Y; Yamaguchi K; Dyson PJ; Therrien B
Dalton Trans; 2010 Sep; 39(35):8248-55. PubMed ID: 20689885
[TBL] [Abstract][Full Text] [Related]
6. Encapsulation of pyrene-functionalized poly(benzyl ether) dendrons into a water-soluble organometallic cage.
Pitto-Barry A; Barry NP; Zava O; Deschenaux R; Therrien B
Chem Asian J; 2011 Jun; 6(6):1595-603. PubMed ID: 21626704
[TBL] [Abstract][Full Text] [Related]
7. Excellent correlation between drug release and portal size in metalla-cage drug-delivery systems.
Barry NP; Zava O; Dyson PJ; Therrien B
Chemistry; 2011 Aug; 17(35):9669-77. PubMed ID: 21735491
[TBL] [Abstract][Full Text] [Related]
8. Derivation of structure-activity relationships from the anticancer properties of ruthenium(II) arene complexes with 2-aryldiazole ligands.
Martínez-Alonso M; Busto N; Jalón FA; Manzano BR; Leal JM; Rodríguez AM; García B; Espino G
Inorg Chem; 2014 Oct; 53(20):11274-88. PubMed ID: 25302401
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, characterisation and in vitro anticancer activity of hexanuclear thiolato-bridged arene ruthenium metalla-prisms.
Furrer MA; Garci A; Denoyelle-Di-Muro E; Trouillas P; Giannini F; Furrer J; Clavel CM; Dyson PJ; Süss-Fink G; Therrien B
Chemistry; 2013 Feb; 19(9):3198-203. PubMed ID: 23344898
[TBL] [Abstract][Full Text] [Related]
10. DNA interactions of monofunctional organometallic ruthenium(II) antitumor complexes in cell-free media.
Novakova O; Chen H; Vrana O; Rodger A; Sadler PJ; Brabec V
Biochemistry; 2003 Oct; 42(39):11544-54. PubMed ID: 14516206
[TBL] [Abstract][Full Text] [Related]
11. Tuning the reactivity of osmium(II) and ruthenium(II) arene complexes under physiological conditions.
Peacock AF; Habtemariam A; Fernández R; Walland V; Fabbiani FP; Parsons S; Aird RE; Jodrell DI; Sadler PJ
J Am Chem Soc; 2006 Feb; 128(5):1739-48. PubMed ID: 16448150
[TBL] [Abstract][Full Text] [Related]
12. Anticancer activity of opened arene ruthenium metalla-assemblies.
Barry NP; Zava O; Furrer J; Dyson PJ; Therrien B
Dalton Trans; 2010 Jun; 39(22):5272-7. PubMed ID: 20442944
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, characterization, and in vitro evaluation of novel ruthenium(II) eta6-arene imidazole complexes.
Vock CA; Scolaro C; Phillips AD; Scopelliti R; Sava G; Dyson PJ
J Med Chem; 2006 Sep; 49(18):5552-61. PubMed ID: 16942028
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, spectroscopic characterization, photochemical and photophysical properties and biological activities of ruthenium complexes with mono- and bi-dentate histamine ligand.
Cardoso CR; de Aguiar I; Camilo MR; Lima MV; Ito AS; Baptista MS; Pavani C; Venâncio T; Carlos RM
Dalton Trans; 2012 Jun; 41(22):6726-34. PubMed ID: 22539182
[TBL] [Abstract][Full Text] [Related]
15. Anticancer activity of tetracationic arene ruthenium metalla-cycles.
Barry NP; Edafe F; Therrien B
Dalton Trans; 2011 Jul; 40(27):7172-80. PubMed ID: 21660364
[TBL] [Abstract][Full Text] [Related]
16. Phenylazo-pyridine and phenylazo-pyrazole chlorido ruthenium(II) arene complexes: arene loss, aquation, and cancer cell cytotoxicity.
Dougan SJ; Melchart M; Habtemariam A; Parsons S; Sadler PJ
Inorg Chem; 2006 Dec; 45(26):10882-94. PubMed ID: 17173447
[TBL] [Abstract][Full Text] [Related]
17. DNA structural distortions induced by ruthenium-arene anticancer compounds.
Gossens C; Tavernelli I; Rothlisberger U
J Am Chem Soc; 2008 Aug; 130(33):10921-8. PubMed ID: 18651736
[TBL] [Abstract][Full Text] [Related]
18. Ruthenium(II) arene PTA (RAPTA) complexes: impact of enantiomerically pure chiral ligands.
Kilpin KJ; Cammack SM; Clavel CM; Dyson PJ
Dalton Trans; 2013 Feb; 42(6):2008-14. PubMed ID: 23187957
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, characterization and biological evaluation of novel Ru(II)-arene complexes containing intercalating ligands.
Nikolić S; Rangasamy L; Gligorijević N; Aranđelović S; Radulović S; Gasser G; Grgurić-Šipka S
J Inorg Biochem; 2016 Jul; 160():156-65. PubMed ID: 26818702
[TBL] [Abstract][Full Text] [Related]
20. Development of organometallic ruthenium-arene anticancer drugs that resist hydrolysis.
Ang WH; Daldini E; Scolaro C; Scopelliti R; Juillerat-Jeannerat L; Dyson PJ
Inorg Chem; 2006 Oct; 45(22):9006-13. PubMed ID: 17054361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
